سعر انهيجليب 12.5 مجم 30 قرص 2025

Inhiglip 12.5 mg (Hikma Pharma): alogliptin 12.5 mg film-coated tablets, 30 tablets; an oral DPP-4 inhibitor for type 2 diabetes.

• Adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common (>=4%): nasopharyngitis, headache and upper respiratory tract infection.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• History of a serious hypersensitivity reaction to alogliptin-containing products (anaphylaxis, angioedema, severe cutaneous reactions).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Acute pancreatitis (discontinue if suspected); heart failure (consider risks in patients with risk factors; discontinue if heart failure develops); serious hypersensitivity; hepatic failure reports (interrupt and investigate liver injury).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hypoglycaemia when used with insulin or insulin secretagogues (lower their dose); severe and disabling arthralgia; bullous pemphigoid.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Insulin or insulin secretagogues (e.g. sulfonylureas)Increased risk of hypoglycaemia; a lower dose of insulin or secretagogue may be required.DailyMed (U.S. National Library of Medicine)

• Limited data with alogliptin in pregnancy are insufficient to inform drug-associated risk; no adverse developmental effects in animals at high exposures; poorly controlled diabetes carries maternal and fetal risks.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No information on alogliptin in human milk (present in rat milk); weigh breastfeeding benefits against the mother's need for the drug.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Alogliptin: Inhibits DPP-4, slowing inactivation of incretin hormones (GLP-1, GIP) and so increasing glucose-dependent insulin release and lowering glucagon.